LSBCF LakeShore Biopharma Co., Ltd
Fundamentals / CIK 0001946399 / CNYLakeShore Biopharma Co., Ltd reported ¥615.0M in revenue and a net loss of ¥99.98M for the fiscal year ended March 31, 2025 (up 7.2% year over year), with a 82.5% gross margin and a -14.0% operating margin.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open LSBCF in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025¥615.0M +7.2% YoY
-
Operating Income FY 2025-¥86.29M -14.0% margin
-
Net Income FY 2025-¥99.98M -16.3% net margin
-
Diluted EPS FY 2025-¥5.22 Split-adjusted
-
Free Cash Flow FY 2025-¥133.7M -21.7% FCF margin
-
Cash & ST Investments Mar 31, 2025¥28.08M Total debt: ¥414.4M
Annual revenue and net income
5 fiscal years (2021 to 2025), reported in CNY.
Financial statements and ratios
Reported in CNY. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in CNY · Newest filing period first.
| Income Statement | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|
| Revenue | ¥615.0M | ¥573.4M | ¥687.2M | ¥502.9M | ¥257.0M |
| Cost of Revenue | ¥107.8M | ¥117.7M | ¥153.4M | ¥117.1M | ¥59.66M |
| Gross Profit | ¥507.2M | ¥455.7M | ¥533.8M | ¥385.9M | ¥197.4M |
| Research & Development | ¥146.4M | ¥302.8M | ¥318.7M | ¥211.2M | ¥94.39M |
| Selling, General & Admin | ¥410.4M | ¥441.3M | ¥345.9M | ¥284.1M | ¥228.8M |
| Total Operating Expenses | ¥593.5M | ¥901.6M | ¥673.2M | ¥504.8M | ¥323.2M |
| Operating Income | -¥86.29M | -¥445.8M | -¥139.4M | -¥119.0M | -¥125.8M |
| EBITDA | -¥49.64M | -¥403.6M | -¥102.7M | -¥87.80M | -¥97.94M |
| Interest Expense | ¥16.70M | ¥47.50M | ¥32.00M | ¥2.80M | ¥5.80M |
| Income Before Tax | -¥100.9M | -¥455.2M | -¥144.3M | -¥101.1M | -¥174.4M |
| Income Tax Expense | -¥947K | -¥21.73M | ¥1.13M | ¥4.94M | ¥17.45M |
| Net Income | -¥99.98M | -¥433.5M | -¥145.5M | -¥106.0M | -¥191.8M |
| Basic EPS | -¥5.22 | -¥40.54 | -¥23.55 | -¥17.10 | -¥46.69 |
| Diluted EPS | -¥5.22 | -¥40.54 | -¥23.55 | -¥17.10 | -¥46.69 |
| Basic Shares Outstanding | 19.2M | 10.7M | 6.2M | 6.2M | 4.1M |
| Diluted Shares Outstanding | 19.2M | 10.7M | 6.2M | 6.2M | 4.1M |
Income Statement (Quarterly) · Reported in CNY · Newest filing period first.
Balance Sheet (Annual) · Reported in CNY · Newest filing period first.
| Balance Sheet | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | ¥28.08M | ¥246.4M | ¥370.4M | ¥271.1M |
| Cash & Short-Term Investments | ¥28.08M | ¥246.4M | ¥370.4M | ¥271.1M |
| Accounts Receivable, Net | ¥500.9M | ¥444.2M | ¥463.1M | ¥308.6M |
| Inventory | ¥227.6M | ¥203.4M | ¥185.4M | ¥166.5M |
| Other Current Assets | -- | -- | ¥901K | ¥854K |
| Total Current Assets | ¥842.2M | ¥903.2M | ¥1.04B | ¥764.8M |
| Property, Plant & Equipment, Net | ¥413.5M | ¥473.3M | ¥571.8M | ¥550.2M |
| Intangible Assets | ¥72.85M | ¥71.25M | ¥78.06M | ¥80.72M |
| Other Non-Current Assets | ¥10.30M | ¥34.36M | ¥20.92M | ¥28.23M |
| Total Non-Current Assets | ¥525.4M | ¥609.9M | ¥683.8M | ¥677.0M |
| Total Assets | ¥1.37B | ¥1.51B | ¥1.72B | ¥1.44B |
| Accounts Payable | ¥49.55M | ¥67.77M | ¥80.44M | ¥30.81M |
| Short-Term Debt | ¥390.4M | ¥318.5M | ¥193.7M | ¥111.7M |
| Other Current Liabilities | ¥5.11M | ¥10.74M | ¥6.95M | ¥7.65M |
| Total Current Liabilities | ¥824.8M | ¥802.2M | ¥658.8M | ¥475.9M |
| Long-Term Debt | ¥23.50M | ¥98.98M | ¥293.8M | ¥253.9M |
| Total Non-Current Liabilities | ¥43.16M | ¥125.6M | ¥332.5M | ¥294.6M |
| Total Liabilities | ¥867.9M | ¥927.8M | ¥991.3M | ¥770.5M |
| Total Debt (incl. Leases) | ¥414.4M | ¥424.5M | ¥498.6M | ¥380.6M |
| Common Stock | ¥29K | ¥26K | ¥12K | ¥8.0K |
| Retained Earnings | -¥2.41B | -¥2.31B | -¥1.87B | -¥1.59B |
| Accumulated Other Comp. Income | -¥57.27M | -¥58.18M | -¥54.41M | ¥83.09M |
| Total Stockholders' Equity | ¥499.8M | ¥585.2M | ¥728.5M | -¥699.0M |
| Total Equity | ¥499.8M | ¥585.2M | ¥728.5M | -¥699.0M |
Balance Sheet (Quarterly) · Reported in CNY · Newest filing period first.
| Balance Sheet | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | ¥28.08M | ¥246.4M | ¥370.4M | ¥271.1M |
| Cash & Short-Term Investments | ¥28.08M | ¥246.4M | ¥370.4M | ¥271.1M |
| Accounts Receivable, Net | ¥500.9M | ¥444.2M | ¥463.1M | ¥308.6M |
| Inventory | ¥227.6M | ¥203.4M | ¥185.4M | ¥166.5M |
| Other Current Assets | -- | -- | ¥901K | ¥854K |
| Total Current Assets | ¥842.2M | ¥903.2M | ¥1.04B | ¥764.8M |
| Property, Plant & Equipment, Net | ¥413.5M | ¥473.3M | ¥571.8M | ¥550.2M |
| Intangible Assets | ¥72.85M | ¥71.25M | ¥78.06M | ¥80.72M |
| Other Non-Current Assets | ¥10.30M | ¥34.36M | ¥20.92M | ¥28.23M |
| Total Non-Current Assets | ¥525.4M | ¥609.9M | ¥683.8M | ¥677.0M |
| Total Assets | ¥1.37B | ¥1.51B | ¥1.72B | ¥1.44B |
| Accounts Payable | ¥49.55M | ¥67.77M | ¥80.44M | ¥30.81M |
| Short-Term Debt | ¥390.4M | ¥318.5M | ¥193.7M | ¥111.7M |
| Other Current Liabilities | ¥5.11M | ¥10.74M | ¥6.95M | ¥7.65M |
| Total Current Liabilities | ¥824.8M | ¥802.2M | ¥658.8M | ¥475.9M |
| Long-Term Debt | ¥23.50M | ¥98.98M | ¥293.8M | ¥253.9M |
| Total Non-Current Liabilities | ¥43.16M | ¥125.6M | ¥332.5M | ¥294.6M |
| Total Liabilities | ¥867.9M | ¥927.8M | ¥991.3M | ¥770.5M |
| Total Debt (incl. Leases) | ¥414.4M | ¥424.5M | ¥498.6M | ¥380.6M |
| Common Stock | ¥29K | ¥26K | ¥12K | ¥8.0K |
| Retained Earnings | -¥2.41B | -¥2.31B | -¥1.87B | -¥1.59B |
| Accumulated Other Comp. Income | -¥57.27M | -¥58.18M | -¥54.41M | ¥83.09M |
| Total Stockholders' Equity | ¥499.8M | ¥585.2M | ¥728.5M | -¥699.0M |
| Total Equity | ¥499.8M | ¥585.2M | ¥728.5M | -¥699.0M |
Cash Flow Statement (Annual) · Reported in CNY · Newest filing period first.
| Cash Flow Statement | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|
| Net Income | -¥99.98M | -¥433.5M | -¥145.5M | -¥106.0M | -¥191.8M |
| Depreciation & Amortization | ¥36.65M | ¥42.19M | ¥36.69M | ¥31.15M | ¥27.91M |
| Stock-Based Compensation | ¥13.56M | ¥9.79M | ¥3.51M | ¥7.76M | ¥76.76M |
| Change in Receivables | -¥59.65M | ¥13.90M | -¥165.2M | -¥99.14M | -¥220.7M |
| Change in Inventory | -¥24.17M | -¥86.26M | -¥18.15M | -¥89.46M | -¥68.73M |
| Change in Payables | -¥18.22M | -¥12.66M | ¥49.63M | ¥14.43M | -¥4.42M |
| Operating Cash Flow | -¥121.0M | -¥295.2M | -¥182.5M | -¥173.5M | -¥246.6M |
| Capital Expenditure | -¥12.71M | -¥44.25M | -¥52.76M | -¥295.3M | -¥104.9M |
| Free Cash Flow | -¥133.7M | -¥339.5M | -¥235.2M | -¥468.9M | -¥351.5M |
| Investing Cash Flow | -¥17.01M | -¥44.25M | -¥56.98M | -¥298.9M | -¥104.2M |
| Common Stock Issued | -- | ¥284.2M | -- | -- | -- |
| Financing Cash Flow | -¥3.58M | ¥205.3M | ¥317.4M | ¥364.6M | ¥739.3M |
| Net Change in Cash | -¥139.1M | -¥123.8M | ¥99.30M | -¥119.4M | ¥388.4M |
Cash Flow Statement (Quarterly) · Reported in CNY · Newest filing period first.
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|
| Gross Margin | 82.5% | 79.5% | 77.7% | 76.7% | 76.8% |
| Operating Margin | -14.0% | -77.7% | -20.3% | -23.7% | -49.0% |
| Net Profit Margin | -16.3% | -75.6% | -21.2% | -21.1% | -74.6% |
| Return on Equity (ROE) | -20.0% | -74.1% | -20.0% | -- | -- |
| Return on Assets (ROA) | -7.3% | -28.6% | -8.5% | -7.4% | -- |
| Current Ratio | 1.02x | 1.13x | 1.57x | 1.61x | -- |
| Quick Ratio | 0.75x | 0.87x | 1.29x | 1.26x | -- |
| Debt to Equity | 0.83x | 0.73x | 0.68x | -- | -- |
| Revenue Growth (YoY) | +7.2% | -16.6% | +36.6% | +95.7% | -- |
| Gross Profit Growth (YoY) | +11.3% | -14.6% | +38.3% | +95.5% | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.